Join Now

Category Archives: BioUtah News

BioUtah Kicks-Off the 2021 Virtual BioHive Summit with Dr. Dean Li, President, Merck Research Laboratories

The BioHive Summit, powered in partnership with BioUtah, on Nov. 12 will live stream a distinguished line-up of speakers and panelists from inside and outside Utah’s burgeoning life sciences industry.

| Tagged , | Leave a comment

New WTC Utah Grants for Doing Business in the Middle East

Join WTC Utah in Dubai, UAE for the largest U.S. government-led trade mission and business development forum.

| Tagged | Leave a comment

Certus Critical Care Awarded Two Department of Defense Grants for Development of Endovascular Device

Grants Totaling Over $3M Earmarked for Life Saving Medical Technology to Combat Massive Blood Loss

| Tagged | Leave a comment

MPF II NEXT Makes its Debut Investment in iVeena Delivery Systems

A clinical stage ophthalmology company, iVeena is developing disease-modifying therapeutics for a rare corneal disorder and an increasingly common form of nearsightedness

| Tagged | Leave a comment

Utah Rep. Blake Moore Tours Logan’s BioHive Community

Yesterday, US Rep. Blake Moore (R-UT-1) visited the burgeoning BioHive community in Logan, touring Utah State University’s (USU0 state-of-the-art BioInnovations Center, Quansys Biosciences and ELITech. Utah’s life sciences industry, from Logan to St. George, is one of the fastest-growing in the nation. “Cache Valley has become a hub for bioscience, and I thank BioUtah for […]

| Leave a comment

PolarityTE Provides Update on Investigational New Drug Application

SALT LAKE CITY, Oct. 7, 2021 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided an update regarding its Investigational New Drug Application (IND) for SkinTE® with a proposed indication for chronic cutaneous ulcers submitted to the Food and Drug Administration (FDA) in July 2021. The Company received […]

| Leave a comment

Renalytix Launching KidneyIntelX in Veterans Health Administration Hospitals

NEW YORK and SALT LAKE CITY, Oct. 07, 2021 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the expansion of its commercial strategy to address early-stage kidney disease in the Veterans Health Administration patient population with the appointment of Jed Fulk to the position of Vice President Sales, Government Accounts. Mr. Fulk […]

| Leave a comment

Stryker: Patient impact: our inspiration

Stryker CEO, Kevin Lobo, recently shared his thoughts about his work at Stryker and what it means to help make a difference for patients

| Tagged | Leave a comment

BioHive Names Katelin Roberts Executive Director

BioHive, Utah’s collective of life sciences and healthcare innovation companies, today announced that Katelin Roberts will serve as the full time Executive Director, effective immediately.

| Tagged | Leave a comment

Recursion is Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis

Recursion announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for REC-4881 for the potential treatment of familial adenomatous polyposis (FAP).

| Tagged | Leave a comment

NIH AWARDS SINTX TECHNOLOGIES PHASE 1 GRANT FOR SN-PEEK 3D PRINTED SPINAL IMPLANTS

SINTX Technologies, Inc., an original equipment manufacturer of advanced ceramics, announced today a Phase 1 grant of $308,301 awarded by the National Institute of Health (NIH) to develop a 3-D printed, composite silicon nitride – polyetheretherketone (SN-PEEK) spinal implant.

| Tagged | Leave a comment

SINTX ARMOR SHIPS FIRST ORDER AND PREPARES FOR MOVE TO UTAH

SINTX Technologies, Inc., an original equipment manufacturer of advanced ceramics, announced today that its newly created and wholly-owned subsidiary, SINTX Armor, will be located in Salt Lake City, Utah and that it has signed a 10-year lease on a facility to house development and manufacturing activities for SINTX Armor.

| Tagged | Leave a comment